TITLE

Recombinant Factor VIIa for Rapid Reversal of Warfaren Anticoagulation in Acute Intracranial Hemorrhage

AUTHOR(S)
Freeman, William D.; Brott, Thomas G.; Barrett, Kevin M.; Castillo, Pablo R.; Deen, Jr, H. Gordon; Czervionke, Leo F.; Meschia, James F.
PUB. DATE
December 2004
SOURCE
Mayo Clinic Proceedings;Dec2004, Vol. 79 Issue 12, p1495
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To assess the effects of recombinant factor VIIa (rFVIIa) on hemorrhage volume and functional outcomes in warfarin-related acute intracranial hemorrhage (ICH), which has a 30-day mortality of more than 50%. PATIENTS AND METHODS: We reviewed the clinical, laboratory, and radiographic features of a consecutive series of 7 patients (median age, 87 years; 5 women) with symptomatic, nontraumatic warfarin-related acute ICH treated with intravenous rFVIIa at St. Luke's Hospital in Jacksonville, Fla. between December 2002 and September 2003. Prestroke baseline functional status was assessed with the modified Rankin Scale. Outcome was assessed with the Glasgow Outcome Scale. RESULTS: The international normalized ratio decreased from a mean of 2.7 before administration of rFVIIa to 1.08 after administration of rFVIIa. The median prestroke score on the modified Rankin Scale was zero. The median presenting score on the Glasgow Coma Scale was 14 (range, 4-15). The mean time from onset to treatment was 6.2 hours. The mean initial dose of rFVIIa was 62.1 µg/kg. One patient underwent placement of an external ventricular drain, and another underwent craniotomy and hematoma evacuation. Five of the 7 patients survived and were dismissed from the hospital with severe disability (Glasgow Outcome Scale, 3): 2 patients died during hospitalization. CONCLUSIONS: Intravenous bolus administration of rFVIIa can rapidly lower the international normalized ratio and appears to be safe for patients with warfarin-related ICH. Prospective controlled studies are needed to determine whether rFVIIa can prevent hematoma expansion and improve neurologic outcomes in patients with warfarin-related ICH.
ACCESSION #
15323706

 

Related Articles

  • Are major bleeding events from falls more likely in patients on warfarin? Garvin, Roger; Howard, Ellen; Crawford, Paul // Journal of Family Practice;Feb2006, Vol. 55 Issue 2, p159 

    The article provides information concerning the evidence of increased risk for major bleeding in elderly patients who fall and are taking warfarin. Based on the study, the risk of intracranial hemorrhage from a fall is much smaller than the benefit gained from reducing risk of stroke in patients...

  • Retrospective assessment of potential interaction between levofloxacin and warfarin. Berta Gracia García; Elisabet Leiva Badosa; María Perayre Badía; Concepción Reynaldo Martínez; Ramón Jodar Masanés // Pharmacy World & Science;Apr2009, Vol. 31 Issue 2, p224 

    Abstract   Objective There is currently a controversy regarding interactions between levofloxacin and warfarin. The aim of this study was to determine the clinical relevance of this interaction in our setting. Setting A university hospital in Barcelona, Spain. Methods We carried out a...

  • Thromboembolic risks of recombinant factor VIIa Use in warfarin-associated intracranial hemorrhage: a case-control study. Chou Sherry H-Y; Cai Xuemei; Rachael G, Konigsberg; Linda M, Bresette; Galen V, Henderson; Farzaneh A, Sorond; Steven K, Feske // BMC Neurology;2012, Vol. 12 Issue 1, p158 

    Background: Recombinant factor VIIa (rFVIIa) may be used for rapid hemostasis in life-threatening hemorrhage. In warfarin-associated intracerebral hemorrhage (wICH), FVIIa use is controversial and may carry significant thromboembolic risks. We compared incidence of baseline thromboembolic risk...

  • Outcomes and Management of Bleeds with the Novel Oral Anticoagulants. Yeh, Calvin H.; Gross, Peter L.; Weitz, Jeffrey I. // Canadian Journal of General Internal Medicine;2013 Supplement 2, p25 

    Novel oral anticoagulants (NOACs) are rapidly replacing warfarin for the prevention and treatment of venous and arterial thrombosis. Bleeding is the major complication of anticoagulation therapy, and NOACs are associated with significantly less intracranial bleeding than warfarin and have rates...

  • Was This the Clover in Which Stalin Ended His Days?  // Orthopedics;May2005, Vol. 28 Issue 5, p442 

    Discusses research on the toxicology of warfarin. Information warfarin; Treatment for warfarin poisoning; Case report published in a 2005 issue of the "Lancet."

  • Warfarin.  // Reactions Weekly;9/29/2012, Issue 1421, p50 

    The article describes the cases of 7 elderly patients who received warfarin for a minor head injury but developed intracranial haemorrhage or subdural haematoma.

  • YenidoÄŸan Bir Bebekte Warfarin Ä°liÅŸkili Ä°ntrakranial Kanama: Vaka Sunumu. SARIAYDIN, Mehmet; KADER, Şebnem; MUTLU, Mehmet; ASLAN, Yakup // Journal of the Child / Cocuk Dergisi;Jun2013, Vol. 13 Issue 2, p77 

    Warfarin is an anticoagulant which is frequently used in persons with mechanical heart valves at risk of thrombosis or embolism. Warfarin therapy during pregnancy can cause serious complications such as congenital malformations and intracranial hemorrhage. Warfarin-associated neonatal bleeding...

  • Tramadol-warfarin interaction.  // WHO Drug Information;2004, Vol. 18 Issue 3, p208 

    The article reports that some individuals are susceptible to interaction between tramadol and warfarin. A pharmacodynamic study has been conducted of the effect on international normalized ratio (INR) of giving tramadol to 19 individuals stabilized on phenprocoumon. Two of the individuals had...

  • Determination of warfarin by sensitized fluorescence using organized media. Smirnova, T.; Nevryueva, N.; Shtykov, S.; Kochubei, V.; Zhemerichkin, D. // Journal of Analytical Chemistry;Nov2009, Vol. 64 Issue 11, p1114 

    The effect of surfactant micelles and albumin on the fluorescence warfarin of and the fluorescence of Eu3+ and Tb3+ sensitized by warfarin and the second ligand is studied. It was shown that sensitized fluorescence in the system Eu3+-tenoyltrifluoroacetone-warfarin allows a 3800-fold reduction...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics